Analysts forecast that NewLink Genetics Corp (NASDAQ:NLNK) will post earnings per share of ($0.69) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for NewLink Genetics’ earnings, with estimates ranging from ($0.80) to ($0.60). NewLink Genetics reported earnings of ($0.46) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The firm is expected to report its next earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that NewLink Genetics will report full year earnings of ($2.65) per share for the current financial year, with EPS estimates ranging from ($2.80) to ($2.55). For the next financial year, analysts forecast that the business will post earnings of ($2.40) per share, with EPS estimates ranging from ($3.02) to ($1.62). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for NewLink Genetics.
NewLink Genetics (NASDAQ:NLNK) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative net margin of 229.19% and a negative return on equity of 63.39%.
Shares of NewLink Genetics (NLNK) opened at $8.62 on Friday. NewLink Genetics has a 12 month low of $5.90 and a 12 month high of $25.17. The company has a market cap of $318.89, a P/E ratio of -3.53 and a beta of 1.10.
Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC grew its position in NewLink Genetics by 241.6% in the fourth quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 13,770 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in NewLink Genetics by 22.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 100,944 shares of the biotechnology company’s stock valued at $819,000 after purchasing an additional 18,712 shares in the last quarter. Creative Planning bought a new position in NewLink Genetics in the fourth quarter valued at $152,000. GSA Capital Partners LLP grew its position in NewLink Genetics by 653.7% in the third quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock valued at $1,345,000 after purchasing an additional 114,620 shares in the last quarter. Finally, Neuberger Berman Group LLC bought a new position in NewLink Genetics in the third quarter valued at $305,000. 52.63% of the stock is owned by institutional investors.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.